Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial

鼻塞 医学 鼻漏 安慰剂 随机对照试验 过敏 人口 内科学 外科 鼻子 免疫学 病理 替代医学 环境卫生
作者
Mark A. Moyad,Larry E. Robinson,Julie M. Kittelsrud,Stuart G. Reeves,Susan E. Weaver,Aireen I. Guzman,Mark E. Bubak
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
卷期号:26 (8): 795-804 被引量:39
标识
DOI:10.1007/s12325-009-0057-y
摘要

INTRODUCTION: Allergic rhinitis (AR) impacts around 25% of the worldwide population. However, cost, safety, and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion. Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound; therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms. METHODS: A 12-week, randomized, double-blind, placebo-controlled clinical trial of 96 healthy subjects with a recent clinically documented history of seasonal allergies and AR was conducted. Participants received once-daily supplementation with 500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product (EpiCor, Embria Health Sciences, Ankeny, Iowa, USA) or placebo during the 12-week period of the highest recorded concentrations of total pollen counts for this Midwest geographic area. Clinical outcome measurements included in-clinic examinations, validated questionnaire and standard diary, and serologic analysis at baseline, 6 and 12 weeks. RESULTS: During the highest pollen count period (weeks 1-6), EpiCor significantly reduced the mean severity of specific AR symptoms, including a significant reduction in nasal congestion (P=0.04), rhinorrhea (P=0.005), and a nonsignificant reduction in ocular discharge symptoms. A significantly (P=0.04) reduced total number of days with nasal congestion (12.5 fewer days) favored EpiCor compared with placebo, as did the nasal congestion section of the quality of life questionnaire (P=0.04). Subjects receiving the intervention also experienced significantly (P=0.03) higher salivary IgA levels. Adverse events were similar to placebo. CONCLUSION: This yeast-derived product appeared to be safe and efficacious, and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被自信雪冥采纳,获得10
刚刚
Gins完成签到,获得积分10
刚刚
刚刚
小超人完成签到 ,获得积分10
刚刚
赛巴斯蒂安212完成签到,获得积分10
刚刚
极品小亮发布了新的文献求助10
1秒前
Liuruijia完成签到 ,获得积分10
1秒前
1秒前
mwx完成签到,获得积分20
1秒前
潇洒书易发布了新的文献求助10
2秒前
HanQing完成签到,获得积分10
2秒前
3秒前
3秒前
qearl发布了新的文献求助10
3秒前
Mi完成签到,获得积分10
3秒前
3秒前
单纯草丛完成签到,获得积分10
4秒前
4秒前
4秒前
贪玩的水壶完成签到 ,获得积分10
4秒前
派大星完成签到,获得积分10
4秒前
KIC完成签到,获得积分10
4秒前
酷波er的应助被大力荷花采纳,获得10
4秒前
小阿志完成签到,获得积分10
4秒前
5秒前
完美世界的应助被醉熏的代秋采纳,获得10
5秒前
bz完成签到,获得积分10
5秒前
谨慎初曼完成签到,获得积分10
5秒前
回星予你发布了新的文献求助10
5秒前
6秒前
6秒前
YXL完成签到,获得积分10
6秒前
漂亮的战斗机完成签到 ,获得积分10
6秒前
guoguo发布了新的文献求助10
7秒前
Emma施施完成签到,获得积分10
7秒前
爱撒娇的天磊完成签到,获得积分10
7秒前
7秒前
王哇噻完成签到 ,获得积分10
7秒前
秋风的应助被jinx采纳,获得20
7秒前
Jasper的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180339
求助须知:如何正确求助?哪些是违规求助? 9570391
关于积分的说明 21811279
捐赠科研通 7776418
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479091